More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment ImplicationsPremiere Date: Thursday, June 16, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, June 20, 2023
|Emma Guttman-Yassky, MD, PhD
Waldman Professor and System Chair
The Kimberly and Eric J. Waldman Department of Dermatology
Director, Center of Excellence in Eczema
Director, Laboratory of Inflammatory Skin Diseases
Icahn School of Medicine at Mount Sinai
New York, NY
Alopecia areata (AA) is a type of non-scarring hair loss. While the exact cause is not fully understood, new insights in disease understanding suggest an autoimmune pathology. The inflammatory pathways associated with AA destroy most of the hair follicle but spare the upper portion, giving rise to the possibility of hair regrowth and new targeted treatments that may improve patient outcomes. Therefore, staying up to date on current and emerging data for AA treatments is necessary to enhance comprehension of AA pathophysiology, assess patients, and inform potential treatment targets.
In the first installment of this three-part virtual Journal Club series, More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment Implications, Dr. Emma Guttman-Yassky will present up-to-date information on the pathophysiology and specific immunologic pathways that affect AA.
At the end of this CE activity, participants should be able to:
- Outline the pathophysiology of AA.
Supported by an educational grant from Pfizer Inc.
Physicians, PAs, and nurse practitioners specializing in dermatology, allergy/immunology, general practice, and/or pediatrics located outside of the United States
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
Through a mutual recognition agreement between the AMA and the DHP, physicians licensed in Qatar completing an activity from a US-based ACCME-accredited CME provider can use ACCME AMA PRA Category 1 Credits™ toward their credit requirements.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Guttman-Yassky reports the following financial relationships:
Consultant: AbbVie Inc; Almirall; Amgen Inc.; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Celgene Corporation; Connect Biopharma; Eli Lilly and Company; EMD Serono; Evidera; Galderma; Ichnos Sciences Inc.; Incyte; Janssen Biotech, Inc.; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Pandion Therapeutics; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; SATO Pharmaceutical, Co., Ltd; Siolta Therapeutics; Target PharmaSolutions, Inc.; UCB, Inc.; and Ventyx Biosciences, Inc.
Grants (Paid to Icahn School of Medicine at Mount Sinai): AbbVie Inc; Almirall; Amgen Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; AstraZeneca; Boehringer Ingelheim; Cara Therapeutics; Celgene Corporation; Eli Lilly and Company; Galderma; Glenmark Pharmaceutical Inc./Ichnos Sciences Inc.; Innovaderm; Janssen Pharmaceuticals, Inc.; Kao Corporation; Kiniksa Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Novan, Inc.; Novartis; Pfizer Inc.; Ralexar Therapeutics, Inc.; Regeneron Pharmaceuticals Inc; and UCB, Inc.
Research Support (Paid to Icahn School of Medicine at Mount Sinai): AbbVie Inc; Almirall; Amgen Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; AstraZeneca; Boehringer Ingelheim; Cara Therapeutics; Celgene Corporation; Eli Lilly and Company; Galderma; Glenmark Pharmaceutical Inc./Ichnos Sciences Inc.; Innovaderm; Janssen Biotech, Inc.; Kao Corporation; Kiniksa Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Novan, Inc.; Novartis; Pfizer Inc.; Ralexar Therapeutics, Inc.; Regeneron Pharmaceuticals Inc; and UCB, Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).